For patients receiving VKA therapy for treatment of VTE, should a shorter INR recall interval vs a longer INR recall interval be used following VKA dose adjustment due to an out-of-target-range INR? 6. For patients receiving maintenance VKA therapy for treatment of VTE, should a longer (eg, 6-12 wk) INR recall interval vs a shorter (eg, 4 wk) INR recall interval be used during periods of stable INR control? 7. For patients with renal dysfunction (creatinine clearance of ,30 mL/min) receiving LMWH therapy for treatment of VTE, should clinicians monitor anti factor Xa concentration to guide LMWH dose adjustment vs no such monitoring? 8. For patients with obesity receiving LMWH therapy for treatment of VTE, should clinicians monitor anti factor Xa concentration to guide LMWH dose adjustment vs no such monitoring? 9. For patients receiving DOAC therapy for the treatment of VTE, should measurement of the DOAC anticoagulant effect vs no measurement of DOAC anticoagulant effect be used during management of bleeding? 10. For patients transitioning from DOAC to VKA, should LMWH or UFH bridging therapy vs overlapping DOAC therapy be used until the INR is within the therapeutic range? 11. For patients receiving anticoagulation therapy for treatment of VTE, should specialized AMS care vs care provided by the patient s regular health care provider be used for anticoagulation management? 12. For patients receiving oral anticoagulation therapy for VTE treatment, should supplementary patient education be offered vs no supplementary patient education? 13. For patients receiving anticoagulation therapy for VTE, should interventions to improve adherence (eg, refill reminders, INR reminders) vs usual care be used? 14. For patients at low to moderate risk of recurrent VTE who require interruption of VKA therapy for invasive procedures, should periprocedural bridging with LMWH or UHF vs interruption of VKA therapy alone be used? 15. 